The US Food and Drug Administration’s agency-wide reorganization could assuage dietary supplement industry stakeholders' concerns by keeping on its nomenclature an office focused on their products but also adding a separate enforcement unit.
The FDA’s unit focused on OTC drugs also continues, though it has a new home within the Center for Drug Evaluation and Research, in the reorganization the agency announced in a
The reorganization follows recommendations the Reagan-Udall Foundation made in January 2023 after its review of the FDA’s food safety programs